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Summary 
Tumor-initiating cells (T-ICs) are a subpopulation of chemoresistant tumor cells that have been 
shown to cause tumor recurrence upon chemotherapy. Identification of T-ICs and their related 
pathways are therefore priorities for the development of new therapeutic paradigms. We 
established chemoresistant hepatocellular carcinoma (HCC) xenograft tumors in 
immunocompromised mice in which an enriched T-IC population was capable of tumor initiation 
and self-renewal. Using this model, we found CD24 to be up-regulated in residual chemoresistant 
tumors when compared with bulk tumor upon cisplatin treatment. CD24
+
 HCC cells were found to 
be critical for the maintenance, self-renewal, differentiation, and metastasis of tumors and to 
significantly impact patients’ clinical outcome. Using a lentiviral-based knockdown approach, 
CD24 was found to be a functional liver T-IC marker that drives T-IC genesis through 
Stat3-mediated Nanog regulation. Our findings point to a CD24 cascade in liver T-ICs that may 
provide an attractive therapeutic target for HCC patients. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world (Jemal et al., 2008). 
The first line treatment for HCC is liver transplantation or surgical resection (Carr, 2004, Kassahun 
et al., 2006). However, most HCCs are inoperable as patients present at advanced stages. Even after 
surgical resection, the long-term prognosis of HCC remains
 
unsatisfactory due to high
 
recurrence 
rates. For HCC patients in advanced stages, chemotherapy via either transarterial 
chemoembolization or a systemic route is the second-line treatment. Unfortunately, the overall 
response rate is unsatisfactory due to the highly chemoresistant nature of the tumor and the toxicity 
of the chemotherapeutic agents (Aguayo and Patt, 2001, Llovet and Bruix, 2003, Kuvshinoff and 
Ota, 2002). Further investigation into the mechanism of chemoresistance of HCCs is needed to 
improve the survival rate. 
 The cancer stem cell hypothesis posits that cancers are maintained in a hierarchical 
organization of rare ‘cancer stem cells’ (or tumor-initiating cells, T-ICs), which divide rapidly into 
amplifying cells and differentiated tumor cells (Dalerba et al., 2007). Owing to this unique survival 
mechanism, this rare population of cells is resistant to the current chemotherapies (All-Hajj, 2007). 
This hypothesis also provides an explanation for the failure of current treatment regimes due to the 
fact that they are largely targeted at eradicating the rapidly proliferating tumor bulk. The existence 
of T-ICs was first evidenced in acute myeloid leukemia (Lapidot et al., 1994) and more recently in 
different solid tumors, including those of the brain (Singh et al., 2003), colon (O’Brien et al., 2007), 
breast (Al-Hajj et al., 2003), prostate (Collin et al., 2005), melanoma (Fang et al., 2005), and 
pancreas (Hermann et al., 2007). Integrative comparative genomic analysis has established 
molecular similarities between T-ICs and normal tissue stem cells, suggesting a role for liver T-ICs 
in hepatocarcinogenesis (Marquardt et al., 2010). Recently, liver T-ICs have been identified by 
several cell surface antigens such as CD133 (Ma et al., 2007 and 2010), CD90 (Yang et al., 2008), 
and EpCAM (Yamashita et al., 2009), and these T-ICs are capable of self-renewal and were found 
to be resistant to chemotherapeutic drugs (Ma et al., 2008). 
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Because T-ICs are relatively resistant to chemotherapy, we enriched for liver T-ICs by 
establishing chemoresistant HCC xenograft tumors in immunocompromised mice, mimicking the 
clinical situation under which HCC patients receive chemotherapy. Using this model, we identified 
CD24, a mucin-like cell surface glycoprotein, to be up-regulated in residual chemoresistant tumors 
upon cisplatin treatment when compared with untreated tumors. To further investigate the role of 
CD24
+
 cells in HCC, we isolated these cells from the HCC cell lines PLC/PRF/5 and HLE and 
HCC clinical samples. Freshly isolated CD24
+
 cells were found to be more quiescent, greater 
ability to form tumors in NOD/SCID mice, the ability to self-renew, differentiation and metastasis. 
The clinical impact of CD24 was also addressed, and it was found to significantly correlate with 
aggressive tumor behavior. Knockdown of CD24 by a lentiviral-based shRNA approach suppressed 
the stem/progenitor cell characteristics, suggesting that CD24 is a functional marker of liver T-ICs. 
Furthermore, we identified Nanog to be an important downstream effector of CD24-mediated HCC 
tumorigenicity and self-renewal. cDNA microarray analysis revealed that regulation of Nanog by 
CD24 was Stat3-dependent. Our findings may provide an attractive therapeutic approach of 
targeting the CD24 cascade in liver T-ICs to achieve better clinical outcomes for HCC patients. 
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Results 
CD24 was elevated in self-renewing liver cancer cells enriched by chemotherapy in an HCC 
xenograft model 
According to the ‘cancer stem cell’ hypothesis, chemotherapy reduces the tumor burden while 
sparing a T-IC population endowed with drug-resistant properties (Ma et al., 2008, Pardal et al., 
2003). In order to determine whether liver T-ICs are enriched upon chemotherapy, a chemoresistant 
xenograft model derived from HCC cell lines was established that mimics the heterogeneity 
observed in patients' tumors. Tumor xenografts derived from PLC/PRF/5 cells were subcutaneously 
inoculated into nude mice. When the tumors reached 4 mm in diameter, the mice were injected 
intra-peritoneally with various doses of cisplatin. Such treatment resulted in variable tumor 
inhibition among the xenografts (Figure 1A). The dosage of cisplatin for establishment of 
chemoresistant tumor was determined experimentally by comparing the tumor response to several 
different dosages ranging from 1 mg/kg to 5 mg/kg. From the dose response curve, 5 mg/kg was 
chosen as the level at which further increase of cisplatin concentration did not further reduce the 
tumor size (Figure 1B). To verify whether cisplatin at 5 mg/kg enriched the proportion of T-ICs in 
the residual chemoresistant tumor, single HCC cells derived from untreated (control group) and 
chemoresistant residual tumors (chemoresistant group) were isolated. The tumorigenicity of the 
HCC cells derived from these two groups was compared after serial orthotopic transplantation of 
5x10
4 
corresponding cells into SCID mice. Because the PLC/PRF/5 cells were labeled with the 
luciferase gene, the tumorigenicity was evaluated using a xenogen imaging system. Compared with 
HCC cells from untreated tumor, enhanced tumor-forming and self-renewal abilities were observed 
in chemoresistant residual HCC cells, indicating successful enrichment for liver T-ICs in this 
chemoresistant HCC xenograft model derived from PLC/PRF/5 cells (Figure 1C). To further 
determine what markers are elevated in self-renewing chemoresistant HCC cells, the messenger 
RNA profiles from tumors derived from the untreated and chemoresistant groups (5 mg/kg) were 
compared using a cDNA microarray containing 34,000 genes (data not shown, unpublished). CD24, 
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but not other currently known liver T-IC markers (CD133, CD90, and EpCAM), was found to be 
up-regulated by two folds in the chemoresistant group compared to the control group. To validate 
this observation, we studied the expression of CD24 by qPCR and immunohistochemistry (IHC) in 
the tumors. Consistent with the cDNA microarray data, CD24 was found to be up-regulated by 
three folds by qPCR (Figure 1D). Similarly, IHC studies also showed that CD24 expression was 
dramatically higher in the chemoresistant group relative to the control group (Figure 1E). To 
exclude the possibility of a cell-type specific effect, CD24 expression was further evaluated in the 
same chemoresistant model using another HCC cell line, Huh-7. By IHC staining, CD24 expression 
was dramatically higher in the chemoresistant group (Figure S1). 
 
CD24 expression in HCC cell lines and human HCC sspecimens  
To determine whether CD24 marks more tumorigenic liver cells, we examined its expression by 
flow cytometry (FACS) analysis in a panel of liver cell lines, including the non-tumorigenic 
immortalized cell line MIHA and the HCC cell lines Huh-7, Hep3B, BEL7402, PLC/PRF/5, HLE, 
BEL7402, MHCC-97L, MHCC-97H, and MHCC-LM3. Variable expression of CD24 was found in 
the HCC cell lines with in vivo tumor forming ability. In contrast, the immortalized 
non-tumorigenic cell line MIHA, which is incapable of tumor formation in vivo showed no CD24 
expression (Figure 1F). These results suggest that CD24 expression might play a role in tumor 
development in vivo. Next, we asked whether CD24 was overexpressed in patient HCC specimens 
when compared with non-tumor counterparts. We performed IHC staining for CD24 on 41 human 
HCC tissue samples as well as their non-tumor counterparts. The percentage of CD24
+
 cells in the 
HCC specimens ranged from 0% to 16%, whereas there was no CD24 expression in the non-tumor 
counterparts. Among all HCC specimens, over 70% (29/41) of the cases showed CD24 expression 
in less than 2% of cells (Figure 1G & 1H). Thus, CD24 was expressed sporadically in human HCC 
specimens. 
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CD24
+ 
HCC cells possessed characteristics of stem/progenitor cells 
T-ICs are believed to possess the stem/progenitor properties of relative quiescence (Friel et al., 
2008), self-renewal (Patrawala et al., 2005), and tumorigenicity in immunodeficient mice (Li et al., 
2007). First, we determined whether CD24
+
 HCC cells were more tumorigenic than their CD24
- 
counterparts in vivo by tumor-forming assay using CD24
+
 and CD24
- 
cells purified from 
PLC/PRF/5 and HLE cell lines. Purified cells were inoculated subcutaneously into NOD/SCID 
mice. A significant difference in tumor incidence was observed between CD24
+
 and CD24
- 
cells 
(Figure 2A & 2B). As few as 500 CD24
+
 cells were sufficient for consistent tumor development in 
NOD/SCID mice (Table S1A & 1B). A key property of stem cells, including T-ICs, is their unique 
ability to undergo self-renewal (Patrawala et al., 2005). One method of evaluating self-renewal 
capacity is by testing serial passage ability. After xenografts derived from sorted PLC/PRF/5 cells 
formed, the corresponding tumors were excised from the primary recipients, dissociated into a 
single-cell suspension, grown in culture for approximately one week, re-sorted into CD24
+
 and 
CD24
- 
cells using an antibody specific to human CD24, and then re-injected into secondary mouse 
recipients. About three weeks, all the secondarily xenografted mice injected with CD24
+
 cells 
showed tumor formation that reconstituted the phenotypic heterogeneity of the primary xenografts 
(Figure 2A & 2B), providing direct evidence of the self-renewal ability of the cell population. 
Consistently, as few as 500 CD24
+ 
cells were sufficient for tumor formation (Table S1C). In 
addition, all secondary xenografts formed around three weeks, a significantly shorter tumor latency 
period than for the primary xenografts. Normal and neoplastic stem-like cells from epithelial organs 
can be expanded as sphere-like aggregates in serum-free EGF-bFGF-supplemented medium and 
undergo serial passage (Liu et al., 2005). To obtain further evidence for the self-renewal ability of 
CD24
+
 cells, we performed a sphere formation assay. Compared with CD24
- 
cells, significantly 
larger and more hepatospheres were observed in CD24
+
 cells isolated from both PLC/PRF/5 and 
HLE cells (Figure 2C), which supports the greater self-renewal capability of CD24
+
 HCC cells. It is 
believed that quiescence is one of the characteristics of stem cells (Friel et al., 2008). To compare 
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the relative quiescence of CD24
+
 and CD24
-
 cell fractions, cell proliferation rate was measured. 
Colony formation assay revealed that CD24
+
 cells derived from PLC/PRF/5 and HLE proliferated 
at a significantly lower rate than CD24
- 
cells (P <0.010 and P <0.001, respectively, t test, Figure 
2D). Finally, we addressed whether CD24
+
 cells had other intrinsic properties of stem cells by 
examining the expression of certain ‘stemness’ associated genes that are crucial in pathways and 
programs that establish and maintain stem cell-like characteristics. Using qPCR analysis, we found 
that CD24
+
 fractions purified from both PLC/PRF/5 and HLE cells had a general overexpression of 
these genes (Figure 2E).  
 
Clinical ssignificance of CD24 in HCC  
We have demonstrated that sorted CD24
+
 cells derived from HCC cell lines possess 
stem/progenitor characteristics (Figure 2). To examine the role of CD24
+
 HCC cells in HCC 
patients, we isolated single HCC cells from fresh HCC clinical samples and separated them into 
CD24
+
 and CD24
- 
cell populations. We examined whether CD24
+
 HCC cells derived from HCC 
clinical samples also possessed tumorigenicity and self-renewal ability. In colony formation assays, 
CD24
+
 HCC cells were able to induce more and larger tumor colonies than their CD24
- 
counterparts (P<0.001, t test) (Figure 3A) and this showed that CD24
+
 HCC cells were more 
tumorigenic than CD24
-
 cells in vitro. To evaluate the in vivo tumorigenicity, two fresh HCC 
patient samples were used. By flow cytometry, corresponding CD24
+ 
and CD24
-
 cells were sorted 
from patient #71 and patient #73, and their CD24 expression was found to be 15% and 2%, 
respectively. As few as 4,000 CD24
+
 HCC cells are able to develop a tumor in NOD/SCID mice, 
while there was no tumor formation with CD24
-
 cells after 70 days of tumor inoculation (Figure 3B 
& 3C). The capacity of CD24
+
 cells for self-renewal was also evidenced by sphere formation 
assays and evaluation of stemness genes by quantitative PCR. CD24
+
 HCC cells preferentially 
expressed stemness genes and were able to survive in anchorage-independent serum-free EFG-FGF 
supplemented medium (Figure 3D & 3E). CD24 expression was previously found to be 
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overexpressed in HCC and has prognostic significance (Huang and Hsu, 1995; Yang et al., 2009). 
Next, we investigated the potential relationship between CD24 expression and the clinical outcome 
of HCC patients. We retrospectively analyzed the CD24 expression in 46 HCC patients by 
quantitative PCR. The cut off value of T/N >3 was used to determine CD24 expression in HCC 
patients. Eighteen (39.1%) of the 46 cases showed more than three-fold CD24 overexpression in 
the HCC tumor tissues as compared with the corresponding non-tumorous liver tissues, and these 
were considered the high CD24 expression group. The correlation between CD24 overexpression 
and the clinico-pathologic features is summarized in Table 1. Patients whose tumors had high 
CD24 expression had a significantly higher risk of tumor recurrence in the first year after surgery 
(P=0.002, 2 test), and higher serum AFP level (P=0.009, 2 test). Their tumors more frequently 
had venous infiltration (P=0.003, 2 test), presented at advanced tumor stages (P=0.010, 2 test). 
Patients with CD24 overexpression in their tumors had significantly shorter disease-free survival 
than those with low CD24 expression (P=0.002, log-rank test) (Figure 3F). Consistently, patients 
with CD24 overexpression had shorter overall survival, though this did not reach statistical 
significance (P=0.113, log-rank test) (Figure 3F). All in all, CD24 overexpression in HCC 
correlated with more aggressive tumor behavior and worse clinical outcome. 
 
CD24
+ 
HCC cells had the capacity to metastasize in vivo  
Venous infiltration is an important pathologic feature determining HCC metastasis and tumor 
recurrence (Arii et al., 1992). As shown in Table 1, high CD24 expression significantly correlated 
with venous infiltration. This finding suggests that CD24
+
 cells are endowed with metastatic 
features. To test this hypothesis, we first isolated CD24
+
 and CD24
- 
cells from PLC/PRF/5 and 
examined their invasive and migratory abilities using matrigel invasion and transwell migration 
assay, respectively. Prior to each experiment, trypan blue assay was performed to show that cell 
viability of sorted cells from both subpopulations was greater than 90% (data not shown). As 
compared to CD24
- 
cells, CD24
+
 cells displayed approximately 3.7-fold and 5-fold higher cell 
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migration and invasion efficiency, respectively (P<0.001, t test) (Figure 4A & 4B). To test the in 
vivo metastatic role of CD24
+
 cells, an experimental metastasis model was employed in which 
1x10
5
 CD24
+
 or CD24
- 
cells were injected into NOD/SCID mice through tail vein injection. After 
40 days, the formation of tumor foci in the lungs was evaluated with a xenogen imaging system. 
Three out of five (60%) mice injected with CD24
+
 cells showed tumor formation in the lungs, 
whereas none of the mice injected with CD24
- 
cells showed tumor formation in the lungs (Figure 
4C & 4D). In addition, lung metastasis was also observed in NOD/SCID mice after subcutaneous 
injection of CD24
+
 derived from patient #71 and #73 (Figure S2A). Histological evidence for the 
lack of tumorigenicity in NOD/SCID mice inoculated with CD24
-
 cells is shown in Figure S2B. 
These data support the hypothesis that CD24
+ 
T-ICs represent a distinct invasive T-IC population 
that contributes to tumor metastasis. Recent studies have suggested that CD133 and EpCAM are 
putative T-IC markers for HCC (Ma et al., 2007, Yamashita et al., 2007). By flow cytometric 
analysis, we examined and compared the expression of each marker in Huh-7 cells. CD24 
expression was found to overlap with that of CD133 and EpCAM, suggesting that these three 
markers share similar self-renewal pathways (Figure S3A). Contrary to CD133 and EpCAM, we 
observed only a very low, if at all, overlapping expression between CD24 and CD90 (~1%) (data 
not shown). In view of this, we proceeded to examine whether CD24 serves a unique function of 
liver T-IC over CD90 using a CD90 lentiviral based shRNA knockdown approach in MHCC97H 
cells, which was found to contain the highest CD24 expression among a panel of liver cell lines 
tested (Yang et al., 2008). CD90-repressed clones (shRNA CD90) or CD90 expressing clones 
(non-target control) were first sorted for CD24
+
 and CD24
-
 cells; and then examined for differential 
tumorigenic capacity (Figure S3B). CD24
+
 liver T-ICs were found to be more tumorigenic than 
CD24
-
 non-T-ICs. Further, the ability of CD24
+ 
CD90 expressing or knockdown cells to initiate 
tumor formation were very similar, with a tumor initiation rate of 83.3% and 75%, respectively 
(Figure S3C). Thus, we concluded that CD24 do serve as a unique function in the T-ICs of HCC.  
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CD24
+ 
HCC cells had the capacity to differentiate in vitro  
To investigate the differentiation capacity of CD24
+
 cells, we first cultivated the cells dissociated 
from fresh HCC clinical tissues in such specified medium as ‘hepatospheres’, to obtain 
undifferentiated cells. These hepatospheres were serially passaged by trypsinization into single 
cells to re-form new hepatospheres and, after three passages, all the floating hepatospheres were 
observed to be CD24
+ 
(data not shown), suggesting the inability of CD24
-
 cells to survive in 
serum-free conditions. To evaluate the differentiation potential of CD24
+ 
cells, hepatospheres were 
cultivated without EGF or FGF in the presence of 10% serum. After one day of culture, floating 
undifferentiated cells attached to the glass, gradually flattened out from the hepatospheres, and 
became large and adherent cells. Upon differentiation, the hepatospheres gained CK18 expression 
and lost CD24 expression, and they acquired a morphology closely resembling the HCC cells 
present in the original tumor (Figure 4E). By qPCR, we found consistent decline in CD24 and 
‘stemness’-associated genes upon differentiation of the hepatospheres derived from HCC patient 
samples (Figure 4F). The same phenomenon was observed upon differentiation of the 
hepatospheres derived from the HCC cell line PLC/PRF/5 (Figure 4G). To further explore the 
capacity of CD24
+ 
cells to differentiate, highly purified CD24
+
 and CD24
- 
cells were separately 
cultured in 10% serum-supplemented medium for two weeks, following which the expression of 
CD24 was analysed in each population by flow cytometry. We found that the CD24
+
 proportion 
dramatically declined after three days, and reverted almost to the pre-sorting level, whereas CD24
- 
cells retained low expression of CD24 even after two weeks, indicating that CD24
- 
cells arose only 
from CD24
+
 cells and not vice versa (Figure 4H). In addition, by single cell sorting, increase in 
CK18 expression was observed in CD24
+
 cells but not in CD24
-
 cells upon differentiation (Figure 
S4). 
 
CD24 knockdown reduced stem/progenitor characteristics in HCC cells  
It is yet to be proven whether T-IC cell surface markers are just physical markers or whether they 
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functionally contribute to the traits of stem/progenitor cells. Therefore, we performed a CD24 
knockdown experiment using a lentiviral-based approach in cells that highly express CD24 (Huh-7 
and PLC/PRF/5). After confirmation of successful knockdown with a 50% to 60% reduction 
(Figure 5A & 5B) in CD24 expression in clones #121 and #278, respectively, in both Huh-7 and 
PLC/PRF/5, we first compared the expression of ‘stemness’-associated genes between CD24 
knockdown clones and non-target controls. Compared with the non-target controls, these genes, 
including Sox2, Oct4, and Nanog, were down-regulated in Huh-7 and PLC/PRF/5 knockdown 
clones (#278) (Figure 5A & 5B). Consistent down-regulation of the above stemness genes was 
observed in clone #121 (data not shown). Next, we examined the tumorigenicity of Huh-7 cells 
upon CD24 knockdown. After four weeks, we found that both the number and size of the tumors 
was lower in clone #278 when compared with the non-target control group (Figure 5C & Table S2). 
The effect of CD24 knockdown on tumorigenicity was also examined in PLC/PRF/5 cells. Either 
CD24 knockdown cells or control cells (15,000) were injected into the liver of SCID mice. The 
incidence of tumor formation was 60% (3/5) whereas it was 20% (1/5) in the CD24 knockdown 
group (Figure 5D). In the control group, all SCID mice showing tumor formation exhibited lung 
metastasis. However, no lung metastasis was observed in the CD24 knockdown group, further 
suggesting the metastatic role of CD24 in HCC (Figure 5E). The effect of CD24 knockdown on cell 
proliferation was also examined with the colony formation assay. We found that CD24 knockdown 
cells proliferated more rapidly than the non-target control cells (Figure 5F). The effect of CD24 
knockdown on self-renewal was also examined by sphere formation assay. We found that CD24 
knockdown cells generated fewer and smaller hepatospheres in their first and second passages 
(Figure 5G). In addition, knockdown of CD24 in Huh-7 cells increased the sensitivity of cells to 
both cisplatin and doxorubicin (Figure S5A). Similarly, by cell sorting approach, CD24
+
 HCC cells 
derived from PLC/PRF/5 were more chemoresistant than CD24
- 
cells (Figure S5B). 
 
CD24 drove tumor initiation and self-renewal by mediating a self-renewal gene, nanog 
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To determine the major downstream mediator of CD24 in tumor initiation and self-renewal, we 
scrutinized the qPCR data for effects of CD24 on ‘stemness’-associated genes by both cell sorting 
and lentiviral-knockdown approach. The effect of CD24 on the expression of ‘stemness’-associated 
genes in both HCC cell lines and clinical samples is summarized in Table S3. Among the genes we 
examined, Nanog and Sox2 were found to be consistently altered upon loss of CD24 in the four 
HCC cell lines and two HCC clinical samples studied. To further identify the major mediator of 
CD24 function, we sought a correlation between the expression of CD24 with Nanog and Sox2 in 
five HCC cell lines that expressed different levels of CD24. In these five HCC cell lines, CD24 
expression positively correlated with Nanog expression but not with Sox2 (Figure 6A & S6A). Next, 
we examined the correlation between CD24 and Nanog by qPCR using the same cohort of HCC 
patients. Consistently, CD24 significantly correlated with Nanog expression in these 46 HCC 
patient samples (P=0.026; r=0.325, Pearson’s correlation) (Table S4, Figure 6B). To determine 
whether CD24 drives tumor initiation and self-renewal by activating Nanog gene expression, we 
overexpressed Nanog in a CD24 knockdown clone (#278) of Huh-7 cells to investigate whether the 
effect of CD24 knockdown could be eliminated upon transfection with Nanog. Using the lentiviral 
approach, Nanog was overexpressed in a CD24 knockdown clone (#278) of Huh-7 cells and the 
expression level was comparable to the non-target control (Figure 6C). After successful 
confirmation of Nanog overexpression in the CD24 knockdown Huh-7 cells, we compared in SCID 
mice the tumor forming abilities of CD24 knockdown Huh-7 cells with and without Nanog 
overexpression. The tumorigenicity of CD24 knockdown cells increased upon Nanog transfection, 
and it was comparable to that of the non-target controls (Figure 6D, Table S5). The effect of Nanog 
overexpression on the self-renewal ability of CD24 knockdown Huh-7 cells was also studied using 
the sphere formation assay. This revealed that CD24 knockdown cells generated greater and larger 
hepatospheres in their first and second passages upon Nanog overexpression (Figure 6E). This 
result provides direct evidence that CD24 mediates tumor initiation and self-renewal by driving up 
Nanog expression.  
 14 
CD24 regulated nanog expression through Stat3 phosphorylation  
Being a transmembrane protein (Sammar et al., 1997), CD24 should be able to transmit 
extracellular signals to the nucleus to activate Nanog expression. In order to identify the 
cytoplasmic mediator linking CD24 and Nanog, a cDNA microarray (the Affymetrix Human 
genome U133 gene chip) was used to compare the gene expression profiles of CD24 knockdown 
Huh-7 cells and non-target control cells. By Ingenuity Pathway analysis, several canonical 
pathways were identified, among which ‘acute phase response signaling’ was found to be the most 
significantly altered (Figure S6B). One of the key components of this signaling cascade is the IL6 
pathway, a pathway important for liver stem cell maintenance, in which phosphorylation of Stat3 at 
the Tyrosine705 residue is critical (Lin et al., 2009, Tang et al., 2008). The pathway analysis 
suggested the importance of Stat3 phosphorylation in the IL6 pathway, as the expression of several 
genes downstream of Stat3 was altered upon CD24 knockdown (Figure S6C). In embryonic stem 
cells, phosphorylated Stat3 was found to bind to the murine Nanog promoter and activate its 
transcription (Suzuki et al., 2006). We therefore hypothesized that CD24 transcriptionally regulated 
Nanog expression through Stat3 phosphorylation. To test this hypothesis, we first examined the 
expression of Stat3 and its phosphorylated form in CD24 knockdown clones of Huh-7 and 
PLC/PRF/5 cells. We found less phosphorylated Stat3 (Y705) upon CD24 knockdown but not so 
for its parental form (Figure 6F); this is consistent with the cDNA microarray finding that there was 
no change in the mRNA level of Stat3. To further examine whether the regulation of Nanog 
expression in HCC cells is Stat3 dependent, we examined pStat3 (Y705) and Nanog expression in 
response to a Stat3 inhibitor (S3I-201) in PLC/PRF/5 and Huh-7 cells. Nanog expression was found 
to be down-regulated upon S3I-201 treatment in a dose-dependent manner (Figure S7A). This 
observation was further confirmed when we found overexpression of CD24 ORF into CD24 
negative cells, MIHA, resulted in a significant increase in pStat3 (Y705) and Nanog expression; 
while addition of varying doses of S3I-201 led to abolishment of this effect (Figure S7B). To 
validate the transcriptional regulation of Nanog by CD24, we transfected a GFP-tagged Nanog 
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promoter into PLC/PRF/5 cells to monitor its activity. By FACS-sorting, the GFP signal was found 
to be notably higher in the CD24
+
 fraction, reflecting up-regulation of Nanog transcription, and this 
signal was decreased upon addition of S3I-201 (Figure 6G). To further examine the potential 
binding between phosphorylated Stat3 and the Nanog promoter, a ChIP-qPCR assay was 
performed. In Figure 6H, we demonstrated binding between phosphorylated Stat3 and Nanog 
promoters in Huh-7 and PLC/PRF/5 cells. Conversely, upon CD24 knockdown, there was a 
decrease of p-Stat3 binding on the Nanog promoters in these two cell lines. CD24 was previously 
found to be associated with Src-associated kinase (Sammar et al., 1997), which phosphorylates 
Stat3 (Byers et al., 2009). By overexpression and knockdown approaches, activated form of Src 
(pY416) was consistently altered but not JAK2, another molecule that has previously been found to 
phosphorylate Stat3 (Hedvat et al., 2009) (Figure S7C-E), which suggests that CD24 potentially 
phosphorylates Stat3 through Src but not JAK. These findings demonstrate the positive link 
between CD24 expression, STAT3 activation and Nanog transcription. 
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Discussion 
According to the ‘cancer stem cell hypothesis’, T-IC populations become enriched upon 
chemotherapy due to their unique survival mechanism. Recently, this theory has been 
experimentally proven in various cancer systems including breast and lung cancer (Bertolini et al., 
2009, Yu et al., 2007). In this study, we successfully enriched for liver T-ICs using a 
chemoresistant HCC xenograft model. In this model, cisplatin-treated HCC cells showed enhanced 
self-renewal capacity and tumorigenicity when compared with untreated control cells. By cDNA 
microarray, we found that CD24 was up-regulated in the enriched T-IC population, and this was 
confirmed by qPCR and IHC staining. To eliminate the possibility that up-regulation of CD24 upon 
chemotherapy was a cell-type specific effect, we confirmed CD24 up-regulation by IHC staining 
using xenografts derived from another HCC cell line, Huh-7.  
The CD24 gene encodes a heavily glycosylated cell surface protein
 
anchored to the membrane 
by phosphatidylinositol (Pirruccello et al., 1986). CD24 is an oncogene, which are overexpressed in 
various
 
human malignancies (Kristiansen et al., 2002, Kristiansen et al., 2003). It also plays a role 
during
 
the embryonal development of pancreatic cells (Cram et al., 1999). Recent studies have 
suggested that CD24 may be a negative T-IC marker with specific regards to breast cancer (Al-Hajj 
et al., 2003). Intriguingly, increasing evidence has shown that CD24
+
 tumor cells are T-ICs for 
gastrointestinal cancers such as colon cancer (Yeung et al., 2010), pancreatic cancer (Li et al., 
2007), and cholangiocarcinoma (Wang et al., 2010). To determine whether CD24
+
 cells were liver 
T-ICs, we isolated CD24
+
 and CD24
-
 fractions from HCC cell lines and human HCC samples by 
cell sorting. We found that CD24
+
 HCC cells showed higher tumorigenicity than their CD24
-
 
counterparts in NOD/SCID mice. In addition, CD24
+
 HCC cells were capable of self-renewal, as 
they could propagate in another mouse recipient upon serial transplantation. The self-renewal 
ability of CD24
+
 HCC cells was further evidenced by the more and larger hepatospheres they 
generated in sphere formation assays when compared with their CD24
-
 counterpart. The above 
phenotype was also associated with increased expression of stemness genes. Consistently, CD24
+
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HCC cells were found to be more quiescent and to proliferate more slowly in colony formation 
assays. Moreover, CD24
+
 HCC cells were able to differentiate into CD24
-
 cells, but not vice versa 
by single cell sorting approach.  
To examine whether CD24 was specific for liver T-ICs, we performed CD24 
immunostaining of 41 paraffin-embedded HCC clinical samples and their non-tumor counterparts. 
We found that only a minority of HCC cells showed CD24 expression, whereas no CD24 
expression was observed in the non-tumor liver tissues. Flow cytometric analysis also suggested 
scanty expression of CD24 in several fresh HCC clinical samples (data not shown). Using qPCR on 
HCC resected specimens; we found that CD24 overexpression was significantly associated with 
shorter disease-free survival of patients. In addition, CD24 overexpression was significantly 
correlated with early recurrence of HCC after surgery in the present study, suggesting the ability of 
CD24
+ 
tumor cells to re-establish tumor growth. These data support a previous study showing that 
CD24 is a useful predictive marker for early recurrence of HBV-related HCC (Woo et al., 2008). It 
has been predicted that T-ICs might also primarily be responsible for the formation of tumor 
metastases (Dalerba and Clarke, 2007). CD24 overexpression was also significantly correlated with 
venous infiltration, which is an important clinico-pathologic feature of HCC metastasis. Both in 
vitro and in vivo data demonstrate that CD24
+ 
HCC cells alone have the capacity to initiate and 
sustain tumor growth, leading eventually to cancer metastasis. Thus far, CD133 and EpCAM have 
been identified as putative T-IC markers for HCC (Ma et al., 2007, Yamashita et al., 2009). 
However, their metastatic potential has not been investigated. Using flow cytometric analysis, we 
found that CD24 expression overlapped with the expression of both CD133 (~90.9%) and EpCAM 
(~55.8%), suggesting that they may share common self-renewal pathways. However, unlike CD24, 
CD133
+ 
liver T-ICs have previously been found to have a greater proliferative potential than 
CD133
- 
counterparts (Ma et al., 2007). We do not, at the moment, have an explanation to why 
CD24 and CD133 subpopulations display different proliferative potential, as demonstrated by 
colony formation assay. Yet, we speculate that since CD24 expression do not completely overlap 
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with CD133 (9.1% CD24
+
CD133
-
) and EpCAM (44.2% CD24
+
EpCAM
-
), it is possible that these 
T-IC markers may display different tumorigenic and metastatic potentials. In terms of their 
tumorigenic potential, 2x10
4
 CD133
+
 and 1x10
4
 EpCAM
+
 HCC cells derived from patient samples 
were previously reported to be needed for efficient tumor formation in immunodeficient mice (Ma 
et al., 2010; Yamashita et al., 2009). And in our current study, we found that as few as 4,000 
CD24
+
 HCC cells were sufficient for consistent tumor initiation.  
Unlike CD133 and EpCAM, CD24 showed only very low overlapping expression with 
CD90. Using a CD90 shRNA knockdown approach, CD90-repressed clones or CD90 expressing 
clones were sorted for CD24
+
 and CD24
-
 cells. The tumorigenicity of CD24
+
 CD90 expressing or 
knockdown cells were found to be very similar indicating that CD24 can serve as a unique function 
in the T-ICs of HCC. In terms of metastatic potential, 5,000 CD90
+
 liver T-ICs was previously 
reported to induce lung metastasis following orthotropic injection in 50% of the animals examined 
(Yang et al., 2008) while in our current study, we found that only 4,000 CD24
+
 liver T-ICs derived 
from patient samples was sufficient to induce lung metastasis following subcutaneous injection in 
100% of the animals tested. These results demonstrate the superiority of CD24 in some aspects 
over currently available liver T-IC markers. 
Using lentiviral-based RNA interference approach, CD24 was found to be functional liver 
T-IC marker. Also, in an orthotopic HCC tumor model, CD24 knockdown not only inhibited the 
growth of tumors but also inhibited metastasis to the lungs of SCID mice. Furthermore, we found 
that stemness genes such as Oct4, Sox2, and Nanog were down-regulated when CD24 was knocked 
down, suggesting a crosstalk between CD24 signaling and stemness gene expression. Interestingly, 
we found a significant correlation between CD24 expression and Nanog expression in a panel of 
HCC cell lines and HCC clinical samples. Nanog is a self-renewal gene that maintains the 
pluripotency of embryonic stem cells (Silva et al., 2009). Recently, Nanog was identified as a new 
oncogene by large-scale oncogenomic analysis (Mattison et al., 2010), and Nanog expression 
regulates human tumor development (Jeter et al., 2009). To determine if CD24 drove tumor 
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initiation and self-renewal through activation of Nanog gene expression, we overexpressed Nanog 
in a CD24 knockdown clone (#278) of Huh-7 cells. We found that the effect of CD24 knockdown 
was eliminated upon transfection of Nanog, demonstrating that CD24 up-regulates Nanog 
expression to initiate tumor formation and self-renewal. However, by western blot analysis, we 
found that CD24 expression did not change upon overexpression of Nanog and inhibition of Stat3 
(data not shown). This indicates that Nanog and Stat3 truly are downstream targets of CD24.  
 By cDNA microarray comparison of gene expression between CD24 knockdown cells and 
control cells, we found that the IL6/Stat3 pathway was significantly down-regulated upon CD24 
knockdown. The IL6/Stat3 pathway has been previously demonstrated to play important roles in 
the maintenance and proliferation of liver T-ICs (Lin et al., 2009, Tang et al., 2008). CD24 is 
associated with Src-associated kinase (Sammar et al., 1997), which phosphorylates Stat3 (Byers et 
al., 2009). By overexpression and shRNA knockdown approaches, pY416-Src was consistently 
altered with phosphorylated Stat3 (Y705) and Nanog expression, which suggests that CD24 might 
act on Stat3 through Src. By ChIP assay, we found binding of phosphorylated Stat3 (Y705) to 
Nanog promoter, which is consistent to the previous study shown in murine system (Suzuki et al., 
2006). Upon CD24 knockdown in Huh-7 and PLC/PRF/5, there was reduced binding between 
phosphorylated Stat3 (Y705) and Nanog promoter. By western blot analysis, we found that less 
phosphorylated Stat3 (Y705) was observed in CD24 knockdown cells. It is controversial whether 
Nanog is regulated in a Stat3-dependent manner (Humphrey et al., 2004). Nanog expression was 
found to be reduced in a dose-dependent manner upon addition of S3I-201, indicating a regulatory 
role of Stat3 on Nanog expression. Using GFP as a reporter of Nanog promoter activity, we found 
that CD24
+
 PLC cells showed higher Nanog promoter activity, and this activity was reduced upon 
addition of S3I-201. This result suggests that CD24 activates Nanog promoter in a Stat3-dependent 
manner. 
Current chemotherapy against HCC usually primarily directs against the bulk population of 
the tumor. Although these therapies are able to initially shrink the primary tumors, they fail to 
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consistently eradicate the lesions, leading to tumor relapse. In this study, we identified CD24
+
 HCC 
cells within these small lesions, and they functioned to initiate tumor growth and self-renewal 
through Stat3-mediated Nanog up-regulation. The identification of CD24 signaling pathways 
provides an attractive therapeutic strategy against this deadly disease. 
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Experimental Procedures 
Human HCC tissue collection and processing. Liver tumor and adjacent non-tumor liver tissue 
specimens were collected from six patients (Patient #3, 36, 38, 51, 71, and 73) (age ranging from 37 
to 82) who underwent hepatectomy for HCC between 2008 and 2010 in the Department of Surgery, 
Queen Mary Hospital, Hong Kong, with Institutional Review Board (IRB) approval. Tumor tissue 
from xenografts and fresh tumors was minced into 1 mm
3
 cubes and incubated with Type IV 
Collagenase (Sigma, St. Louis, MO) for 5-10 minutes at 37°C. A single-cell suspension was 
obtained by filtering the supernatant through a 100-μm cell strainer (BD Biosciences, San Jose, 
CA). Cell viability was assessed by trypan blue exclusion staining and counting using a 
hemocytometer. For fresh clinical tumors, removal of CD45
+
 cells from within the tumor was done 
with a CD45 depletion kit (Miltenyi Biotech, Germany).  
 
Isolation of CD24
+
 and CD24
− 
populations by flow cytometry and magnetic bead cell sorting. For 
magnetic cell sorting, cells were labeled with PE-conjugated CD24 antibody (clone ML5) (BD 
Pharmingen, San Jose, CA) followed by anti-PE microbeads (Miltenyi Biotec, Germany). Sorting 
was carried out using the Miltenyi Biotec MACS Cell Separation Kit according to the 
manufacturer’s instructions. Magnetic separation was performed up to three times to obtain a 
CD24
+
 population more than 95% pure. Aliquots of CD24
+ 
and CD24
− 
sorted cells were evaluated 
for purity with a FACSCalibur machine and CellQuest software (BD Biosciences San Jose, CA). 
For isolation of CD24
+
 and CD24
-
 cell populations, cells were stained with PE-conjugated CD24 
antibody (BD Biosciences, San Jose, CA) and with isotype-matched mouse immunoglobulin as a 
control. Samples were analyzed and sorted on a BD FACSAria (BD Biosciences San Jose, CA). 
For the positive and negative populations, only the top 10% most brightly stained cells and the 
bottom 10% most dimly stained cells were selected, respectively. Aliquots of CD24
+ 
and CD24
− 
sorted cells were evaluated for purity with a FACSCalibur machine and CellQuest software (BD 
Biosciences San Jose, CA).  
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In Vivo tumorigenicity experiments. Different numbers of cells were injected subcutaneously 
either into severe combined immunodeficient (SCID)-beige or non-obese diabetic (NOD)/SCID 
mice. For an orthotopic tumor model, approximately 15,000 PLC/PRF/5 cells in 30 L of culture 
medium were injected into the left liver lobe of the SCID-beige mice using a method described 
previously (Fu et al., 1991). For those HCC cells labeled with luciferase, imaging was performed 
using a Xenogen IVIS 100 cooled CCD camera (Xenogen, California) on Day 40. The mice were 
given intraperitoneal injections with 200 µL of 15 mg/mL D-luciferin 15 min before imaging. For 
imaging, the mice were placed in a light-tight chamber, the acquisition time ranged from 3 sec to 1 
min, and pseudoimages of the emitted light in photons/s/cm
2
/steradian superimposed over the 
gray-scale photographs of the animal were taken.  
 
Chemoresistant tumor model. Subcutaneous xenografts were established using the PLC/PRF/5 and 
Huh-7 HCC cell line. The animals used to test the treatment were 4- to 6-week-old male athymic 
nude mice (BALB/c-nu/nu). Treatment was started once the size of the xenograft reached 
approximately 4 mm in diameter. The mice were randomly assigned into four groups, each 
consisting of three mice. They were treated with cisplatin intra-peritoneally every 4 days for 4 
weeks at either 1) cisplatin (1
 
mg/kg), 2) cisplatin (2 mg/kg) or 3) cisplatin (5 mg/kg). 
 
Statistical analyses. All statistical analyses were
 
performed using the statistical software SPSS 17 
for Windows (SPSS Inc., Chicago, IL). Fisher’s exact test was used to assess the correlation 
between clinico-pathological parameters and CD24 overexpression for HCC patients. Student’s t or 
Mann-Whitney test was used for continuous data wherever appropriate. The survival curves were 
assessed by the Kaplan-Meier method, and the statistical difference between two groups was 
evaluated by log rank test. P values less than 0.05 were considered statistically
 
significant. 
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Figure Legends 
Figure 1. Up-regulation of CD24 in self-renewing liver cancer cells in chemoresistant HCC 
xenograft model. (A) Nude mice with xenograft tumors of 4 mm in diameter were separated into 4 
groups and given different dosages (1 mg/kg, 2 mg/kg, 5 mg/kg, and no-drug control) of cisplatin at 
embedded intervals of 4 days for 4 weeks. (B) The dosage of 5 mg/kg was found to be optimal to 
achieve enrichment of chemoresistant cells, because further administration of drug from day 14 
onwards did not cause significant shrinkage of the tumors, indicating that the majority of cells 
remaining in the small tumors were insensitive to cisplatin. (C) When the cells dissociated from the 
‘resistant group’ and ‘untreated group’ tumors were injected orthotopically into secondary SCID 
mice recipients, 5  104 cells from the ‘resistant group’ were sufficient to form tumors, whereas no 
tumors were formed from the ‘untreated group’ cells. (D) By qPCR, it was shown that CD24 was 
2.9-fold higher in the PLC/PRF/5-derived ‘resistant group’ tumor cells. (E) Similarly, higher 
expression of CD24 at the protein level was shown by IHC analysis of paraffin-embedded tumor 
tissue. CD24-positivity in the PLC/PRF/5 and Huh-7 derived tumor was found to be increased in 
the ‘chemoresistant group’ when compared with the ‘untreated group’. See also Figure S1. (F) By 
FACS analysis, it was found that MIHA, a non-tumorigenic liver cell line, did not express CD24, 
whereas the HCC cell lines tested varied in their expression levels, ranging from 6.4±2.6% in 
MHCC-97L to 97.7±1.5% in Huh-7 cells. (G &H) By IHC, it was shown that in clinical specimens, 
the non-tumorous liver tissues away from the HCC tumors stained negative for CD24, whereas in 
the tumorous tissues the expression of CD24 was scarce (29/41, i.e. 70.7% of cases examined had 
<2% positivity) and usually in few isolated cells. Error bars represent standard deviation (SD) from 
at least three independent experiments. 
 
Figure 2. CD24
+ 
HCC cells possessed traits of stem/progenitor cells. (A) Representative images 
of the primary-sorted PLC/PRF/5 and HLE and secondary PLC/PRF/5 cell-induced tumor 
formation. See also Table S1. Right flanks were injected with CD24
+
 cells while left flanks were 
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injected with CD24
-
 cells. Red arrow indicates the site of tumor formation for HLE cells (B) 
Paraffin-embedded tissue of the xenotransplanted tumors were processed for H&E staining and 
IHC to detect CD24 expression. These representative images show that in cases of tumor formation, 
tumor cell heterogeneity, in terms of both cell morphology and CD24 expression, was observable. 
(C) By sphere forming assay, the in vitro self-renewal ability was enhanced in CD24
+
 cells from 
PLC/PRF/5 and HLE (left column). Secondary spheres formed from dissociating both spheres also 
demonstrated enhanced serial sphere-forming capacity in CD24
+
 cells, respectively (right column). 
(D) By colony formation assay on the sorted cells of PLC/PRF/5 and HLE), it was demonstrated 
that CD24
+
 HCC cells had a significantly lower proliferation rate when compared with CD24
-
 cells 
respectively (P <0.010 and P <0.001, respectively, t test). (E) CD24+ cells from the two HCC 
cell lines, PLC/PRF/5 and HLE, overexpressed several genes related to ‘stemness’ when compared 
to CD24
-
 cells. (p<0.05; p<0.01) Error bars represent standard deviation (SD) from at least 
three independent experiments. 
 
Figure 3. Clinical relevance of CD24 expression. (A) When cells from a fresh clinical HCC 
sample (Patient #38) were sorted magnetically into CD24
+
 and CD24
-
 fractions, the CD24
+
 cells 
displayed significantly enhanced anchorage-independent growth in the soft-agar colony formation 
assay, indicating higher in vitro tumorigenicity. (B) As few as 4000 CD24
+
 HCC cells (4/4) from 
two clinical HCCs induced tumor formation. Right flanks were injected with CD24
+
 cells while left 
flanks were injected with CD24
-
 cells. Red arrows indicate the site of tumor formation. (C) 
Paraffin-embedded tissues of the xenotransplanted tumors were processed for H&E staining and 
IHC to detect CD24 expression. (D) CD24
+
 cells from primary HCC samples overexpressed several 
genes related to ‘stemness’ when compared with CD24- cells. (p<0.05; p<0.01) (E). By sphere 
forming assay, the in vitro self-renewal ability was enhanced in CD24
+
 cells from fresh HCC tumor 
(Patients #36, #38 and #51). (F) Kaplan-Meier curves for disease-free and overall survival were 
compared according to the CD24 expression in tumor tissues. The overall and disease-free survival 
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of HCC patients with CD24 overexpression in their tumors were 36.7 and 6.6 months as compared 
with 94.2 and 42.4 months in patients with low CD24 expression (P=0.113 and 0.002, respectively, 
log-rank test). Error bars represent standard deviation (SD) from at least three independent 
experiments. 
 
Figure 4. CD24
+
 HCC cells had the capacity to differentiate and metastasize in vivo. (A&B) 
Using trans-well migration and invasion assays, it was shown that the CD24
+
 fraction of sorted 
PLC/PRF/5 cells had enhanced migratory (P<0.001, t test) and invasive properties (P<0.001, t 
test) in vitro. (C&D) By experimental metastatic assay in NOD/SCID mice which was evaluated by 
bioluminescent imaging, it was found that CD24
+
 PLC/PRF/5 cells injected intravenously 
successfully colonized the lungs in 3 of 5 mice, whereas the CD24
- 
cells did not colonize, 
indicating enhanced in vivo metastatic ability. (E) By immunofluorescence staining, spheres of 
stem-like cells derived from clinical HCC cells displayed strong expression of CD24, and CD24 
expression (green color) was lost and CK18 (marker for differentiated hepatoyctes; red color) was 
gained near peripheral region upon differentiation. The cells are counterstained with DAPI. (F&G) 
By comparing the gene expression of spheres of stem-like cells with their differentiated progenies, 
it was found that, for both PLC/PRF/5 cell line and clinical HCC cells (Patient #3), CD24 
expression was relatively higher in the spheres than in the parental cells. The ‘stemness’ of the 
spheres was also reflected by the overexpression of several ‘stemness’-associated genes. (H) Upon 
culture in serum-containing medium for 2 weeks, FACS-sorted CD24
+
 PLC/PRF/5 cells gradually 
reconstituted the original proportion of CD24-expressing cells, whereas CD24
-
 cells failed to give 
rise to the original heterogeneity of CD24 expression. Error bars represent standard deviation (SD) 
from at least three independent experiments. See also Figures S2, S3 and S4. 
 
Figure 5. CD24 knockdown reduced characteristics of liver T-ICs. (A&B) Knockdown of 
CD24 in Huh-7 and PLC/PRF/5 cells resulted in down-regulation of several genes related to 
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‘stemness’ as compared to the non-target control (NTC). (p<0.05; p<0.01, t test) (C) CD24 
knockdown (shCD24) HCC cells exhibited reduced tumor-forming incidence when compared with 
NTC cells. See also Table S2. Right flanks were injected with NTC cells while left flanks were 
injected with shCD24 cells. Corresponding paraffin-embedded tissue of the xenotransplanted 
tumors were processed for H&E staining and IHC to detect CD24 expression. (D) The effect of 
CD24 knockdown on tumorigenicity of PLC/PRF/5 cells was evaluated using xenogen 
bioluminescence imaging. Representative image of tumor developed from PLC/PRF/5 cells derived 
from NTC (left) and shCD24 (right) and corresponding paraffin-embedded tissue of the 
xenotransplanted tumors were processed for H&E staining and IHC to detect CD24 expression. (E) 
H & E staining of paraffin-embedded lung tissue from SCID mice after orthotopic injection of NTC 
cells. Black arrows indicate the tumor foci within the lung tissue. (F) Knockdown of CD24 in 
Huh-7 and PLC/PRF/5 cells resulted in significant increase in proliferative rate respectively 
(P=.017 and P=.032, respectively, t test). (G) Knockdown of CD24 also reduced the size and 
number of hepatospheres formed in Huh-7 and PLC/PRF/5 cells (P<0.001, t test). In addition, 
knockdown of CD24 decreased the ability of cells to form secondary hepatospheres (P<0.001, t 
test). Error bars represent standard deviation (SD) from at least three independent experiments. See 
also Figure S5. 
 
Figure 6. CD24 drove tumor formation and self-renewal via Stat3-mediated Nanog regulation. 
(A) Nanog expression in different HCC cell lines was evaluated by qPCR and found to 
significantly correlate with CD24 expression (P=0.012, r= 0.955, Pearson’s Correlation). (B). 
CD24 expression significantly correlated with Nanog expression in 46 HCC patients (P=0.026, 
r=0.325, Pearson’s Correlation). (C) Nanog was successfully transfected in a CD24 knockdown 
clone (#278) of Huh-7 cells and the expression level was comparable to the non-target control. (D) 
The tumorigenicity of CD24 knockdown cells increased upon Nanog transfection. Representative 
image of tumor developed from Huh-7 derived from shCD24 (left) and shCD24-Nanog (right). (E) 
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In addition, Nanog overexpression in shCD24 knockdown cells also increased the sizes of and 
number of hepatospheres formed in Huh-7 and PLC/PRF/5 cells (P<0.001, t test). In addition, 
Nanog overexpression increased the ability of cells to form primary and secondary hepatospheres 
in shCD24 cells respectively (P<0.001, t test). (F) Decreased level of phosphorylated Stat3 (Y705) 
but not its parental form was observed after CD24 knockdown in Huh-7 and PLC/PRF/5 cells. (G) 
Quantitative assessment of GFP-positive cells by flow cytometry for Nanog promoter activity. 
Flow cytometry analysis showed a 4.5-fold increase in the percentage of GFP-positive cells in 
CD24
+
 PLC/PRF/5 cells when compared with CD24
- 
cells, and its percentage decreased after 
incubation of S3I-201 at 200 M. Immunofluorescence staining also revealed increase of GFP 
signal in CD24
+
 cells when compared with its CD24
-
 counterpart. (H) A marked decrease of pStat3 
bound on the upstream of transcriptional start site of Nanog was found upon CD24 knockdown 
Huh-7 and PLC/PRF/5 cells as compared with the corresponding vector control in ChIP assay. 
Normal rabbit antibody added served as a negative control. Error bars represent standard deviation 
(SD) from at least three independent experiments. See also Figures S6 and S7 and Tables S3, S4 
and S5. 
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Table 1. Clinico-pathologic correlation of CD24 expression in HCC patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 Significant difference 
‡ Fisher's exact test  
† χ2 test  
§ Total number <46 due to missing data  
 
Clinico-pathological variables 
CD24 over-expression 
 p-value 
≤ 3-fold > 3-fold 
Recurrence in the first year (n = 46) 
 
No 22 6 
0.002
*†
 
 
Yes 6 12 
Venous infiltration (n = 43) 
 
Absence 19 3 
0.003
*†§
 
 
Presence 9 12 
Serum AFP level (n = 36) 
 
Low (≤ 20 ng/ml) 16 4 
0.009*
†§
 
 
High (> 20 ng/ml) 6 10 
TNM stage (n = 43) 
 
Early stage (I-II) 15 2 
0.010*
†§
 
 
Late stage (III-IV) 13 13 
Microsatellites (n = 46) 
 
Absence 23 10 
0.051
†
 
 
Presence 5 8 
Age (n = 46) 
 
Young (≤ median, 54) 13 12 
0.179
†
 
 
Old (> median, 54) 15 6 
Differentiation status (n = 36) 
 
Well differentiated 7 3 
 0.456
‡§
 
 
Moderately to poorly differentiated 13 13 
Tumor size (n = 45) 
 
Small (≤ 5 cm) 14 7 
0.565
†§
 
 
Large (> 5 cm) 14 10 
HBV association (n = 46) 
 
Negative of HBsAg  11 8 
0.729
†
 
 
Positive of HBsAg 17 10 
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Supplemental Figures and Legends 
 
Figure S1. Up-regulation of CD24 in a chemoresistant HCC xenograft model derived from 
Huh-7 cells. (A) Cisplatin at 5 mg/kg was administered to nude mice carrying tumors derived from 
the cell line Huh-7. (B) CD24 was found to be overexpressed in the “resistant group” of Huh-7-
derived tumors upon IHC analysis. Related to Figure 1.  
 
Supplemental Figures and Text
Figure S2. Histological analysis of lung and skin of NOD/SCID mice. (A) Histological analysis 
showed lung metastasis after subcutaneous inoculation of CD24
+
 cells derived from patient #71 and 
#73. (B) Lack of tumorigenicity in the skin of NOD/SCID mice inoculated with CD24
-
 cells 
derived from patient #71. Related to Figure 4. 
 
Figure S3. CD24 serves unique function in T-IC of HCC. (A) CD24 expression significantly 
overlapped with the expression of the markers CD133 and EpCAM. By FACS analysis on Huh-7 
cells, the majority of CD24
+
 cells expressed the two other reported HCC T-IC markers, EpCAM 
(55.8%) and CD133 (90.9%). 100% EpCAM
+
 cells were CD24
+
, and 98.9% CD133
+
 cells were 
CD24
+
.  (B) CD90 was knocked down in MHCC-97H cells by lentiviral based approach.  (C) As 
few as 500 CD24
+
 HCC cells from MHCC-97H induced tumor formation. Right flanks were 
injected with CD24
+
 cells while left flanks were injected with CD24
-
 cells. Black arrows indicate 
the site of tumor formation. Tumorigenicity of CD24
+ 
cells is comparable between CD90 
knockdown cells (75%) and control cells (83.3%).  Related to Figure 4. 
 
Figure S4. Differentiation capacity of CD24
+
 HCC cells by single cell sorting approach. CD24
-
 
and CD24
+
 single cells from PLC/PRF/5 cells were isolated by single cell sorting. Corresponding 
cells are seeded onto 96 well plates and grown in 10% FBS supplemented medium. After 3 weeks, 
CK18 expression was evaluated by Cells-to CT™ kit (Applied Biosystems, Foster city, CA). CK18 
was 4 fold more in CD24
+
 cells when compared with CD24
-
 cells. Upon differentiation, there is no 
apparent increase in CK18 expression in CD24
-
 cells while there is 3.69-fold increase in CK18 
expression in CD24
+
 cells. Error bars represent standard deviation (SD) from at least three 
independent experiments.  Related to Figure 4. 
 
        
Figure S5. The effect of CD24 altered expression on chemosensitivity of HCC cells. (A) Upon 
CD24 knockdown in Huh-7 cells, CD24 knockdown cells are more chemosensitive to cisplatin 
(27.3% vs 12.3%) and doxorubicin (39.3% vs 24.4%) when compared with control cells after 
treatment for 24 hours at 5 µg/mL and 3 µg/mL respectively. (B) By Annexin V staining, CD24
+ 
cells derived from PLC/PRF/5 is more chemoresistant to cisplatin (35.4% vs 71.1%) and 
doxorubicin (38.6% vs 78.2%) when compared with CD24
-
 cells after treatment for 24 hours at  10 
µg/mL and  6 µg/mL, respectively. Related to Figure 5. 
 
Figure S6.  Significance of Stat3 phosphorylation in CD24 signaling pathway. (A) Poor 
correlation between Sox2 and CD24 expression in the HCC cell lines. (B)  Ingenuity Pathway 
analysis showed 8 most significant canonical pathways altered upon CD24 knockdown in Huh-7 
cells. (C) Ingenuity Pathway analysis demonstrated the significance of Stat3 in IL-6 pathway upon 
knockdown of CD24 in Huh-7 cells. Error bars represent standard deviation (SD) from at least 
three independent experiments. Related to Figure 6. 
  
Figure S7. CD24 phosphorylates Stat3 (Y705) through Src. (A) Levels of phosphorylated Stat3 
(Y705) and Nanog were down-regulated in dose-dependent manner upon administration of S3I-201. 
(B) CD24 ORF was transfected into CD24 negative MIHA cells. Levels of phosphorylated Stat3 
(Y705) and Nanog were up-regulated but this effect was abolished upon administration of S3I-201 
in dose-dependent manner.  (C) pY416-Src, an active form of Src, but not JAK2 was decreased 
upon CD24 knockdown in Huh-7 and PLC/PRF/5 cells. (D) pY416-Src but not JAK2 and its 
phosphorylated form was increased upon CD24 overexpression in MIHA cells. (E) Addition of 
JAK inhibitor at 50µM did not overcome the increase of pStat3 (Y705) in CD24 overexpressing 
MIHA cells, which suggests that CD24 did not phosphorylate Stat3 through JAK2. Related to 
Figure 6. 
 
Supplemental Tables 
Table S1. Tumorigenicity of CD24
-
 and CD24
+
 HCC cells in NOD/SCID mice. (A) 
Subcutaneous in vivo tumor development by CD24
-
 and CD24
+
 cells sorted from PLC/PRF/5 in 
NOD/SCID mice. (B) In vivo tumor development experiments of CD24
-
 and CD24
+
 cells sorted 
from HLE in NOD/SCID mice. (C) Subcutaneous in vivo tumor development of serially 
transplanted CD24
-
 and CD24
+
 cells sorted from CD24
+
 HCC cell-derived xenograft tumors in 
NOD/SCID mice. Related to Figure 2. 
 
                 
Table S2. In vivo tumor development of shCD24 and non-target control cells from Huh-7 in 
SCID mice. Related to Figure 5. 
 
             
Table S3. Expression of stemness associated genes including -catenin, Nanog, Notch1, Sox2, 
Oct4, Nestin, Smo, Bmi-1, ABCB5, ABCG2, ABCB1, ABCC1, and ABCC2 in CD24 deficient 
cells by both cell sorting and knockdown approach. Related to Figure 6. 
 
Table S4. Correlation between CD24 and Nanog expression in 46 HCC clinical samples. 
Related to Figure 6. 
 
                     
Table S5. In vivo tumor development experiments of shCD24 and Nanog-shCD24 cells from 
Huh-7 in SCID mice. Related to Figure 6. 
 
                  
Supplemental Experimental Procedures 
Cell lines and cell culture. The human HCC cell lines MHCC-97L, MHCC-97H, MHCC-LM3 
(from Liver Cancer Institute, Fudan University, China) (Li et al., 1997), Huh-7, HLE, PLC/PRF/5 
(Japanese Cancer Research Bank, Tokyo, Japan), and Hep3B (American type Culture Collection, 
HB-8064) were maintained in DMEM with high glucose (Gibco BRL, Grand Island, NY) 
supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL), 100 mg/mL penicillin G, 
and 50 g/mL streptomycin (Gibco BRL) at 37C in a humidified atmosphere containing 5% CO2. 
MIHA was kindly provided by Dr. J.R. Chowdhury, Albert Einstein College of Medicine, New 
York (Brown et al., 2000). 
 
Patient samples. Human HCC and corresponding non-tumorous liver samples were collected at the 
time of surgical resection at Queen Mary Hospital, the University of Hong Kong, from 2001 to 
2003. After collection from surgical resection, all samples were immediately snap-frozen in liquid 
nitrogen before storage at -80C. 
 
Plasmids and reagents. Cisplatin was obtained from Calbiochem (La Jolla, CA) and Stat3 inhibitor 
(S3I-201) and JAK inhibitor I (sc-204021) were from Santa Cruz Biotechnology (Santa Cruz, CA). 
Lentiviral-based GFP tagged human Nanog promoter and was purchased from System Biosciences 
(Mountain View, CA). CD24 and Nanog ORF were purchased in GeneCopoeia (Rockville, MD) 
and GenTarget (San Diego, CA) respectively. 
 
cDNA microarray. Total RNA was isolated using TRIZOL Reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. The quality of total RNA was checked with an 
Agilent 2100 bioanalyzer. The RNA was then amplified and labeled with MessageAmp II-Biotin 
Enhanced Single Round RNA Amplification Kit (Ambion Inc., TX). In brief, double-stranded 
cDNA was generated by reverse transcription from 1 g of total RNA with an oligo(dT) primer 
bearing a T7 promoter. The double-strand cDNA was used as a template for in vitro transcription to 
generate biotin-labeled cRNA. After fragmentation, 15 g of cRNA was hybridized to the GeneChip 
array for 16 hr. The GeneChips were washed and stained using the GeneChip Fluidics Station 400 
(Affymetrix Inc. Santa Clara, CA) and then scanned with the GeneChip Scanner 3000 
(Affymetrix). Genome-wide expression profiles were analyzed by the gene chip system Human 
U133 Plus 2.0 (Affymetrix). RNA quality control, sample labeling, GeneChip hybridization, and 
data acquisition were performed at the Genome Research Centre, the University of Hong Kong. To 
compare the gene expression patterns, hybridization intensity in the samples was normalized with 
the Affymetrix global scaling method (Affymetrix). Computational analyses were performed using 
Genespring gx v.11 software (Silicon Genetics). Scanned output files were analysed using Robust 
Multichip Average (RMA) methods with Genespring GX software, Affymetrix. Transcripts with 
more than a two-fold difference level were defined as differentially expressed. Microarray data are 
available publicly at http://www.ncbi.nlm.nih.gov/geo/(Geo accession number, GSE28057). 
 
Lentiviral-based transfection into HCC cells. For luciferase labeling of HCC cells, Huh-7 and 
PLC/PRF/5 cells were labeled with luciferase using a lentiviral-based approach as previously 
described (Lee et al., 2007). For suppression of CD24 and CD90 in HCC cells, lentiviral particles 
(DFCI-Broad RNAi Consortium, Boston) expressing shRNAs against human CD24 and CD90 
were used to downregulate cd24 and cd90 mRNA. Transduced cells were selected with 2 µg/mL 
puromycin.  
 
Sphere formation assay. A total of 200 single HCC cells were plated onto 24-well polyHEMA 
(Sigma)-coated plates. Cells were grown in DMEM/F12 medium (Invitrogen, Carlsbad, CA) for 10 
days supplemented with 4 µg/mL insulin (Sigma-Aldrich, St. Louis, MO), B27 (Invitrogen, 
Carlsbad, CA), 20 ng/mL EGF (Sigma-Aldrich, St. Louis, MO), and 20 ng/mL basic FGF 
(Invitrogen, Carlsbad, CA). For serial passage of primary spheres, the primary spheres were 
collected, subsequently dissociated with trypsin, and resuspended in DMEM/F12 medium with the 
above supplements. 
 
Proliferation assay. Cells were seeded at a density of 1,000 cells per well and allowed to grow for 
five to seven days. Cell proliferation was assessed by a colorimetric assay using crystal violet as 
described previously (Ng et al., 2000). 
 
Anchorage independent growth assay. Cells were suspended in soft agar and growth medium in 6-
well plates at a density of 1,000 cells per well. After 2-3 weeks, colonies (10 cells) were counted 
under the microscope at five fields per well and photographed. 
 
Migration and invasion assays. The migration assay was performed as described (Wong et al., 
2005). The cell invasion assay was performed with self-coated Matrigel (BD Biosciences, San Jose, 
CA) on the upper surface of a transwell chamber. The invasive cells that had invaded through the 
extracellular matrix layer to the lower surface of the membrane were fixed with methanol and 
stained with crystal violet. Photographs of three randomly selected fields of the fixed cells were 
captured and cells were counted. The experiments were repeated independently three times. 
 
Annexin V staining. Cells were stained in binding buffer, 7-AAD and FITC-conjugated Annexin V 
as provided by the Annexin-V-FLUOS Staining Kit (Roche Diagnostics) according to 
manufacturer's instructions. Analysis was determined by a FACSCalibur flow cytometer and 
CellQuest software (BD Biosciences). 
 
Single cell sorting. Viable CD24
- 
and CD24
+
 cells from a single cell suspension of PLC/PRF/5 
were sorted into wells of a 96-well microtitre plate using a FACSAria cell-sorter equipped with an 
automated cell  deposition unit (ACDU) and using 488-nm laser light. For single cell deposition, 
cells were sorted using the 70µm nozzle with the sheath pressure set at 70 PSI using the sort 
precision mode set at single cell. Dead cells were excluded from the sort based on their forward and 
side scatter characteristics using an electronic gate, before applying sort gates to define CD24
+
 
expressing cells for collection. The number of cells deposited in each well was one cell per well. 
Plates were maintained at 37°C in a humidified incubator with 5% CO2 in either physiologic 
oxygen (2–5%).  Plates were manually screened and wells scored as positive if a cell colony was 
found.  Selected colonies were expanded and used for future analysis.  
 
Flow cytometric analysis. The antibodies used included phycoerythrin (PE)-conjugated CD24 (BD 
PharMingen, San Jose, CA), allophycocyanin (APC)-conjugated monoclonal mouse anti-human 
CD133/2 (Miltenyi Biotec, Aubum, CA), and fluorescein isothiocyanate (FITC)-conjugated 
monoclonal mouse anti-human epithelial antigen (DAKO, Carpentaria, CA). Cells were incubated 
in phosphate-buffered saline (PBS) containing 2% fetal bovine serum (FBS) and 0.1% sodium 
azide followed by PE, APC- or FITC-conjugated antibodies. Isotype-matched mouse 
immunoglobulins served as controls. The samples were analyzed using a FACSCalibur flow 
cytometer and CellQuest software (BD Biosciences, San Jose, CA). 
 
Chromatin immunoprecipitation (ChIP) assay. The cells were processed for ChIP assays using 
Pierce Agarose ChIP kit (Thermo Fisher Scientific, Rockford, IL). Briefly, cells were cross-linked 
for 10 min with 1% formaldehyde and lysed. Lysate pellets were resuspended and sonicated with a 
Microson sonifier XL-2000 (Misonix). Protein-DNA complexes were immunoprecipitated using 
either phosphorylated Stat3 (Y705) antibody (Cell Signaling Technology Danvers, MA) or Normal 
rabbit IgG (Thermo Fisher Scientific, Rockford, IL) bound to protein A/G agarose, eluted, and 
digested with proteinase K. For PCR analysis of the ChIP samples before amplicon generation,
 
QIAquick-purified immunoprecipitates were dissolved in 50 µL
 
of water. Standard PCR reactions 
using 3µL of the immunoprecipitated
 
DNA were performed with a SYBR Green PCR kit (Applied 
Biosystems) using GPH1002937(-)17A (Superarray Bioscience, Frederick,
 
MD) which generates a 
PCR amplicon centered 16381 base pairs upstream of the NM_024865.2 (Nanog) transcirption start 
site.  Bioinformatics analysis is based on the Human Genome Build from the UCSC Genome 
Browser Feb. 2009 (GRCh37/hg19) Assembly. Calculation
 
of pStat3 (Y705) occupancy on the 
Nanog promoter was performed according to the ChIP-qPCR primer assay
 
data analysis template 
from Superarray Bioscience (Frederick,
 
MD). 
 
Quantitative PCR (qPCR) analysis. Total RNA was isolated using Trizol reagent according to the 
manufacturer’s protocol (Invitrogen, Carlsbad, CA). Complementary DNA (cDNA) was 
synthesized using a GeneAmp® Gold RNA PCR Kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instructions and then subjected to PCR with a SYBR Green PCR 
kit with primers the sequences of which are provided in Supplementary Methods. For single cell 
sorting experiment, RNA extraction and  cDNA synthesis were carried out  using the Power SYBR 
Green Cells-to-CT™-kit (Applied Biosystems), according to manufacturer’s instructions. The 
amplification protocol consisted of
 
incubations at 94°C for 15 seconds, 63°C for 30 seconds,
 
and 
72°C for 60 seconds. Incorporation of the SYBR Green
 
dye into PCR products was monitored in 
real time with an ABI 7900HT Sequence Detection System and SDS 1.9.1 software (Applied 
Biosystems) and subsequently analyzed using RQ Manager 1.2 software (Applied Biosystems),
 
thereby allowing the threshold cycle (CT) at
 
which exponential amplification of the products began 
to be determined. The amount
 
of target cDNA was calculated
 relative to that of β-actin cDNA. 
 
Western blot analysis. Western blots were
 
developed using an ECL Plus kit (Amersham 
Biosciences, Piscataway, NJ). The primary antibodies included rabbit anti-human Nanog, anti-
human Stat3 (79D7), phospho-Src (Y416), JAK2 (D2E12), phospho-JAK2 (Tyr1007/1008), mouse 
monoclonal XP rabbit anti-human phospho-Stat3 (Tyr705) (D3A7) (Cell Signaling Technology 
Danvers, MA), mouse anti-human CD90 (Abcam, Cambridge, MA) and mouse anti-human β-actin 
(Santa Cruz Technology, Santa Cruz, CA). After washing, the membrane was incubated with 
horseradish peroxidase–conjugated anti-mouse or rabbit or goat antibody (Amersham) and then 
visualized by enhanced chemiluminescence plus according to the manufacturer’s protocol. 
 
Immunostaining, immunofluorescence staining and histopathology. For paraffin-embedded 
tissues, sections were deparaffinized in xylene and rehydrated in graded alcohols and distilled water. 
Slides were processed for antigen retrieval by a standard microwave heating technique. Specimens 
were incubated with goat anti-human CD24 (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA) in 
a dilution of 1:100. Subsequent immunodetection was performed using the standard rapid EnVision 
technique. The reaction was then developed with the DAKO Liquid DAB_Substrate-Chromogen 
System (DAKO, Carpentaria, CA). Sections were counterstained with Mayer’s hematoxylin. 
Stained slides were imaged on an Aperio Scanscope® CS imager (Vista, CA), generating 0.43 
µm/pixel whole slide images. These images were compiled, and CD24 expression was quantitated 
using the Aperio Spectrum® software with a pixel count algorithm. 
 
Immunofluorescence was performed on differentiating hepatospheres. First, floating hepatospheres 
were adhered onto chamber slides and differentiated in the presence of 10% FBS for 24 hours; 
subsequently they were fixed and permeabilized with 0.1%
 
Triton X-100 and fixed with 4% 
paraformaldehyde in PBS. The cells were
 
incubated with FITC-conjugated mouse anti-human 
CD24 (clone ML5) (1:100) (BD Pharmingen, San Jose, CA) and PE-conjugated monoclonal mouse 
anti-human Cytokeratin 18 (2X44) (Santa Cruz Biotechnology, Santa Cruz, CA), and subsequently 
counterstained with DAPI for 5 minutes at room temperature (AppliChem GmbH, Germany). All 
images
 
were visualized under a fluorescent microscope. 
 
For histological analysis, tissues were fixed in formalin, embedded in paraffin, cut into 4-m 
sections and stained with hematoxylin and eosin stain as described (Lee et al., 2007).
  
 
Experimental metastasis model. A total of 1x10
4
 luciferase-labeled cells were suspended in 100L 
of complete medium and then injected into the tail veins of NOD/SCID mice to enter into 
circulation. At 40 days after tumor injection, focus formation was inspected by xenogen imaging, 
observing either the whole anaesthetized mouse or the lungs that were removed immediately after 
sacrificing the mice. The lungs were then collected for paraffin embedding. 
 
Pathway analysis. The Ingenuity Pathway Analysis Tool was used to examine the functional 
associations among genes and generate a gene network with high significance on the basis of more 
interconnected genes being present than would be expected by chance. The significance of each 
network was estimated by the scoring system provided by Ingenuity. The scores were determined 
by the number of differentially expressed genes within each of the networks and the strength of the 
associations among network members. Once over-represented genes that are functionally relevant 
in the gene networks were identified, we validated their functional association by using the 
independent pathway analysis tool PathwayAssist (Version 3.0, Ariadne Genomics). 
Primer sequences for qPCR analyses. 
 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) GenBank No. 
CD24 TGAAGAACATGTGAGAGGTTTGAC GAAAACTGAATCTCCATTCCACAA NM_013230 
CK18 TCT CCCCGGACAGCATGA CCGGTAGTTGGTGGAGAA NM_000224 
β-actin CATCCACGAAACTACCTTCAACTCC GAGCCGCCGATCCACACG NM_001101 
β-catenin ACAACTGTTTTGAAAATCCA CGAGTCATTGCATACTGTCC NM_001098209 
Nanog AATACCTCAGCCTCCAGCAGATG TGCGTCACACCATTGCTATTCTTC NM_024865 
Notch1 CCTGAGGGCTTCAAAGTGTC CGGAACTTCTTGGTCTCCAG NM_017617 
Oct4 CTTGCTGCAGAAGTGGGTGGAGGAA CTGCAGTGTGGGTTTCGGGCA NM_002701 
Sox2 AAATGGGAGGGGTGCAAAAGAGGAG CAGCTGTCATTTGCTGTGGGTGATG NM_003106 
Bmi-1 TGGAGAAGGAATGGTCCACTTC GTGAGGAAACTGTGGATGAGGA NM_005180 
Smo TGGTCACTCCCCTTTGTCCTCAC GCACGGTATCGGTAGTTCTTGTAGC NM_005631 
Nestin CTGCGGGCTACTGAAAAGTT AGGCTGAGGGACATCTTGAG NM_006617 
ABCG2 TCATCAGCCTCGATATTCCATCT GGCCCGTGGAACATAAGTCTT NM_004827 
ABCB1 AAATTGGCTTGACAAGTTGTATATGG CACCAGCATCATGAGAGGAAGTC NM_000927 
ABCB5 TCTGGCCCCTCAAACCTCACC TTTCATACCGCCACTGCCAACTC NM_178559 
ABCC1 CTCCTCCTATAGTGGGGACATCAG GTAGTCCCAGTACACGGAAAG NM_004996 
ABCC2 ATGCAGCCTCCATAACCATGA CTTCGTCTTCCTTCAGGCTATTCA NM_000392 
 
Short-hairpin RNA sequences. 
Gene (sequence number) Sequence 
CD24 (278) cd24-sh1-CCGGTCTTCTGCATCTCTACTCTTACTCGAGTAAGAGTAGAGATGCAGAAGATTTTTG 
CD24 (121) cd24-sh2- CCGGCGCAGATTTATTCCAGTGAAACTCGAGTTTCACTGGAATAAATCTGCGTTTTTG 
CD90 cd90-sh-CCGGCGAACCAACTTCACCAGCAAACTCGAGTTTGCTGGTGAAGTTGGTTCGTTTTTG 
Non-target control   CCGGTTGTGCTCTTCATCTTGTTGCCGGCAACAAGATGAAGAGCACCAATTTTTG 
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